AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/22/21

Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...

Aurinia Pharmaceuticals (NASDAQ:AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in after-hours trading. Aurinia said it plans to use proceeds for clinical development and c...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees...

Bristol Myers Squibb (NYSE: BMY) is reportedly interested in acquiring Aurina Pharmaceuticals (NASDAQ: AUPH) . In this Motley Fool Live video recorded on Oct. 27 , Fool contributors Keith Speights and Brian Orelli discuss whether this deal would be a smart move ...

Image source: The Motley Fool. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcr...

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2021 Earnings Conference Call November 03, 2021 8:30 AM ET Company Participants Dana Lynch – Investor Relations and Corporate Communications Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded at a new 52-week high today of $33.94. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 4.5 million shares. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides produc...

On Oct. 22, Bloomberg News reported that Bristol Myers Squibb (NYSE: BMY) was considering a takeover bid for the autoimmune drugmaker Aurinia Pharmaceuticals (NASDAQ: AUPH) . Since then, additional rumors have surfaced that other pharma giants such as GlaxoSmithKline ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~5.3% in the pre-market after reporting a mixed financial performance for Q3 2021. While the company beat the consensus as revenue at $14.7M showed a sequential improvement of ~122%, the earnings lagged expectations. Following the ...

Aurinia Pharma (NASDAQ:AUPH): Q3 GAAP EPS of -$0.39 misses by $0.06. Revenue of $14.66M beats by $0.51M. Shares +1.56% PM. Press Release Gross margin for the three and nine months ended September 30, 2021 was approximately 98% and 97% respectively. “We are very pleased with Q3 res...